Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.83 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19735248 | 0.95 | KIF11 (0.74) | KIF11NPC1RAB9AALDH1A1CYP2A6 | |
| SCHEMBL20805743 | 0.95 | KIF11 (0.74) | KIF11NPC1RAB9AALDH1A1CYP2A6 | |
| SCHEMBL23666164 | 0.91 | KIF11 (1.00) | KIF11NPC1MKNK1MKNK2RAB9A | |
| SCHEMBL1623940 | 0.91 | KIF11 (1.00) | KIF11NPC1MKNK1MKNK2RAB9A | |
| SCHEMBL29988549 | 0.89 | KIF11 (0.66) | KIF11MKNK1MKNK2ALDH1A1CYP2A6 | |
| SCHEMBL23928360 | 0.89 | KIF11 (0.66) | KIF11MKNK1MKNK2ALDH1A1CYP2A6 | |
| SCHEMBL23959721 | 0.84 | KIF11 (0.59) | KIF11NPC1MKNK1MKNK2RAB9A | |
| SCHEMBL25878173 | 0.84 | KIF11 (0.58) | KIF11NPC1MKNK1MKNK2RAB9A | |
| Pyridine SCHEMBL28773854 | 0.83 | KIF11 (0.56) | KIF11NPC1RAB9ALMNAMAPT | |
| SCHEMBL2254917 | 0.82 | CYP2A6 (0.62) | KIF11NPC1MKNK1MKNK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930329-B1 | 1,3,5-TRIAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME AS COMPONENT | TOSOH CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-7994316-B2 | 1,3,5-triazine derivative, production method thereof and organic electroluminescence device comprising this as a composing component | TOSOH CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | TOSOH CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1930329-A1 | 1,3,5-TRIAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME AS COMPONENT | Tosoh Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | KCNJ2, KCNA4, KCNJ4 | KIF11 3826/4885NPC1 3821/4885MKNK1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.